Latest Insider Transactions at Avantor, Inc. (AVTR)
This section provides a real-time view of insider transactions for Avantor, Inc. (AVTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Avantor, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Avantor, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 25
2023
|
Meghan Henson EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
800
-1.95%
|
$19,200
$24.62 P/Share
|
Feb 25
2023
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
467
-0.45%
|
$11,208
$24.62 P/Share
|
Feb 25
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
299
-0.16%
|
$7,176
$24.62 P/Share
|
Feb 25
2023
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,040
-1.91%
|
$48,960
$24.62 P/Share
|
Feb 24
2023
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,347
+19.38%
|
-
|
Feb 24
2023
|
Gerard Brophy EVP, Biopharma Production |
BUY
Grant, award, or other acquisition
|
Direct |
20,308
+14.71%
|
-
|
Feb 24
2023
|
Kitty Sahin EVP, Strategy&Corp Development |
BUY
Grant, award, or other acquisition
|
Direct |
12,185
+23.86%
|
-
|
Feb 24
2023
|
Michael Stubblefield President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
99,004
+7.14%
|
-
|
Feb 24
2023
|
Sheri Lewis EVP, Global Ops & Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
12,185
+13.73%
|
-
|
Feb 24
2023
|
Justin Miller EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,138
+7.91%
|
-
|
Feb 24
2023
|
James Bramwell EVP Sales, Customer Excellence |
BUY
Grant, award, or other acquisition
|
Direct |
20,308
+16.23%
|
-
|
Feb 24
2023
|
Meghan Henson EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,185
+22.92%
|
-
|
Feb 24
2023
|
Christophe Couturier EVP, AMEA |
BUY
Grant, award, or other acquisition
|
Direct |
9,138
+8.11%
|
-
|
Feb 24
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Grant, award, or other acquisition
|
Direct |
20,308
+9.74%
|
-
|
Feb 24
2023
|
Thomas A Szlosek EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
22,339
+17.29%
|
-
|
Feb 23
2023
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
421
-2.43%
|
$10,104
$24.59 P/Share
|
Feb 23
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
1,893
-1.91%
|
$45,432
$24.59 P/Share
|
Feb 23
2023
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,422
-0.62%
|
$178,128
$24.59 P/Share
|
Feb 23
2023
|
Sheri Lewis EVP, Global Ops & Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
970
-1.48%
|
$23,280
$24.59 P/Share
|
Feb 23
2023
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
468
-0.48%
|
$11,232
$24.59 P/Share
|
Feb 23
2023
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Payment of exercise price or tax liability
|
Direct |
569
-0.67%
|
$13,656
$24.59 P/Share
|
Feb 23
2023
|
Meghan Henson EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
816
-2.76%
|
$19,584
$24.59 P/Share
|
Feb 23
2023
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
3,078
-3.16%
|
$73,872
$24.24 P/Share
|
Feb 23
2023
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
416
-0.43%
|
$9,984
$24.59 P/Share
|
Feb 23
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
213
-0.13%
|
$5,112
$24.59 P/Share
|
Feb 23
2023
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,082
-2.29%
|
$49,968
$24.59 P/Share
|
Feb 22
2023
|
Christophe Couturier EVP, AMEA |
SELL
Open market or private sale
|
Direct |
19,160
-16.47%
|
$459,840
$24.12 P/Share
|
Feb 20
2023
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-1.18%
|
$28,008
$24.54 P/Share
|
Feb 20
2023
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
435
-2.45%
|
$10,440
$24.54 P/Share
|
Feb 20
2023
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,253
-4.47%
|
$102,072
$24.54 P/Share
|
Feb 20
2023
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,026
-1.24%
|
$360,624
$24.54 P/Share
|
Feb 20
2023
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Payment of exercise price or tax liability
|
Direct |
1,066
-1.24%
|
$25,584
$24.54 P/Share
|
Feb 20
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
3,072
-3.0%
|
$73,728
$24.54 P/Share
|
Feb 20
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-0.24%
|
$9,552
$24.54 P/Share
|
Feb 20
2023
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-0.99%
|
$28,008
$24.54 P/Share
|
Feb 20
2023
|
Michael Wondrasch EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,356
-1.39%
|
$32,544
$24.54 P/Share
|
Feb 02
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
11,339
-9.97%
|
$283,475
$25.06 P/Share
|
Jan 31
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
2,515
-1.47%
|
$57,845
$23.9 P/Share
|
Jan 31
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Grant, award, or other acquisition
|
Direct |
44,669
+20.71%
|
-
|
Jan 31
2023
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,187
-16.26%
|
$556,301
$23.9 P/Share
|
Jan 31
2023
|
Thomas A Szlosek EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
53,636
+26.5%
|
-
|
Jan 31
2023
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,942
-7.44%
|
$182,666
$23.9 P/Share
|
Jan 31
2023
|
Justin Miller EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
26,818
+20.07%
|
-
|
Jan 31
2023
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
15,221
-11.8%
|
$350,083
$23.9 P/Share
|
Jan 31
2023
|
Gerard Brophy EVP, Biopharma Production |
BUY
Grant, award, or other acquisition
|
Direct |
38,737
+23.1%
|
-
|
Jan 31
2023
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
91,140
-7.0%
|
$2,096,220
$23.9 P/Share
|
Jan 31
2023
|
Michael Stubblefield President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
223,482
+14.66%
|
-
|
Jan 31
2023
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
7,658
-6.09%
|
$176,134
$23.9 P/Share
|
Jan 31
2023
|
Christophe Couturier EVP, AMEA |
BUY
Grant, award, or other acquisition
|
Direct |
26,818
+17.57%
|
-
|
Jan 02
2023
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-0.8%
|
$21,357
$21.09 P/Share
|